Alkermes
Alkermes plc, a leading biopharmaceutical company headquartered in Ireland, focuses on developing innovative therapies for central nervous system (CNS) disorders and addiction. Founded in 1987, Alkermes has established a strong presence in the global healthcare market, with significant operations in the United States and Europe. The company is renowned for its unique drug delivery technologies and a robust portfolio of products, including treatments for schizophrenia, depression, and opioid dependence. Alkermes' commitment to addressing complex medical needs has positioned it as a key player in the biopharmaceutical industry, with notable achievements in advancing patient care through its proprietary formulations. With a focus on scientific excellence and patient-centric solutions, Alkermes continues to drive innovation and improve outcomes for individuals affected by serious mental health conditions.
DitchCarbon Score
How does Alkermes's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Alkermes's score of 33 is higher than 59% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Alkermes's reported carbon emissions
In 2023, Alkermes reported total greenhouse gas emissions of approximately 15,753,000 kg CO2e for Scope 1 and about 16,726,000 kg CO2e for Scope 2, resulting in a combined total of around 32,480,000 kg CO2e for both scopes. This marks a slight decrease from 2022, where emissions were approximately 16,997,000 kg CO2e for Scope 1 and 16,813,000 kg CO2e for Scope 2, leading to a total of about 33,810,000 kg CO2e. Alkermes has not set specific reduction targets under the Science Based Targets initiative (SBTi) nor does it have documented climate pledges. The company’s emissions data is self-reported and does not include Scope 3 emissions, which are often significant in the pharmaceutical industry. The company has made strides in improving its emissions intensity, reporting approximately 250 kg CO2e per employee and 50 kg CO2e per square metre of floor area in 2023. These metrics indicate a focus on operational efficiency and sustainability within its facilities. Overall, while Alkermes has not established formal reduction targets, its ongoing emissions tracking and reporting reflect a commitment to transparency and accountability in its climate impact.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 13,960,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 17,785,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - | - | - | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Alkermes is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
